论文部分内容阅读
目的分析替比夫定与拉米夫定治疗慢性乙型肝炎临床效果差异。方法 98例慢性乙型肝炎患者,随机分为甲组和乙组,各49例。甲组患者采用替比夫定治疗,乙组患者应用拉米夫定进行治疗。对两组疗效及安全性进行观察对比。结果甲组患者治疗总有效率为95.92%,乙组患者为77.55%,甲组患者的临床疗效高于乙组,差异具有统计学意义(P<0.05)。甲组患者病毒反跳发生率为2.04%,乙组为16.33%,甲组病毒反跳发生率明显低于乙组,差异具有统计学意义(P<0.05)。两组患者不良反应发生率对比差异无统计学意义(P>0.05)。结论替比夫定治疗慢性乙型肝炎的疗效较拉米夫定更好,可减少反跳的发生,且不良反应少,具有较好的疗效与安全性,具有临床应用价值。
Objective To analyze the clinical effects of telbivudine and lamivudine in the treatment of chronic hepatitis B patients. Methods A total of 98 patients with chronic hepatitis B were randomly divided into group A and group B, with 49 cases in each group. A group of patients treated with telbivudine, B patients treated with lamivudine. The two groups were observed and compared the efficacy and safety. Results The total effective rate of treatment in group A was 95.92% and in group B was 77.55%. The clinical efficacy of group A was higher than that in group B, the difference was statistically significant (P <0.05). The incidence of virus rebound in group A was 2.04%, in group B was 16.33%. The incidence of group A viral rebound was significantly lower than that in group B (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The efficacy of telbivudine in the treatment of chronic hepatitis B is better than that of lamivudine, which can reduce the occurrence of rebound and less adverse reactions, which has good curative effect and safety, and has clinical value.